SpeeDx kondigt een samenwerkingsovereenkomst met GSK aan voor de levering van tests en technologie

De tests en de technologie van SpeeDx zullen worden gebruikt om GSK antibiotische klinische proeven te steunen

SYDNEY-(BUSINESS WIRE)- SpeeDx Pty. Ltd., een ontwikkelaar van innovatieve moleculaire diagnostische oplossingen, heeft een samenwerkingsovereenkomst met GSK ondertekend, om een combinatie van bestaande tests en de ontwikkeling van op maat gemaakte tests te verstrekken om bepaalde GSK antibiotische klinische proeven en nieuwe productontwikkeling te steunen.

Dit persbericht bevat multimedia. Bekijk hier de volledige versie: https://www.businesswire.com/news/home/20190624005302/en/

“Wij zijn blij met deze uitbreiding van het nut en de toepassing van onze tests en technologie,” zegt Colin Denver, SpeeDx CEO.

SpeeDx announce a collaborative agreement with GSK to supply tests and technology

SpeeDx tests and technology will be used to support GSK antibiotic clinical trials

SYDNEY–(BUSINESS WIRE)– SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has signed a collaborative agreement with GSK, to provide a combination of existing tests and custom test development to support certain GSK antibiotic clinical trials and new product development.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190624005302/en/

“We welcome this extension of the utility and application of our tests and technology,” said Colin Denver, SpeeDx CEO. “SpeeDx has a demonstrated commitment to improve patient care, and our tests currently used in clinical practice are supporting Resistance Guided Therapy, positively impacting cure rates and helping to minimise the spread of antimicrobial resistant infections.”

About SpeeDx

Founded in 2009, SpeeDx is an Australian-based private company with offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information about SpeeDx please see: https://plexpcr.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20190624005302/en/

Contacts

Australia, New Zealand and Europe

Madeline O’Donoghue – SpeeDx

+61 406 582 808

United States

Rick Roose – RCI Healthcare Public Relations

+1 415 202 4445

Check out our twitter: @NewsNovumpr